Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note issued on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group restated a “hold” rating on shares of Agile Therapeutics in a report on Monday, March 18th.

Agile Therapeutics Stock Performance

NASDAQ AGRX opened at $0.41 on Monday. The business has a fifty day moving average price of $0.49 and a 200 day moving average price of $1.31. The company has a market cap of $2.84 million, a P/E ratio of -0.04 and a beta of 1.25. Agile Therapeutics has a one year low of $0.20 and a one year high of $6.71.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Thursday, March 28th. The specialty pharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter. The business had revenue of $3.62 million during the quarter.

Hedge Funds Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its holdings in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the quarter. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities and Exchange Commission. 10.92% of the stock is currently owned by institutional investors and hedge funds.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.